Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 83550
                    [Title] => Boehringer Ingelheim sets largest cardiovascular protection trial
                    [Summary] => MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors.


The study, announced at the European Society of Hypertension meeting, will examine the effects of the angiotensin III recepto antagonist (ARB) Micardis or telmisartan, on these patients. About 5,000 patients worldwide will be enrolled in the study.


                    [DatePublished] => 2001-06-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

MICARDIS

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 83550
                    [Title] => Boehringer Ingelheim sets largest cardiovascular protection trial
                    [Summary] => MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors.


The study, announced at the European Society of Hypertension meeting, will examine the effects of the angiotensin III recepto antagonist (ARB) Micardis or telmisartan, on these patients. About 5,000 patients worldwide will be enrolled in the study.


                    [DatePublished] => 2001-06-18 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Boehringer Ingelheim sets largest cardiovascular protection trial

June 18, 2001 - 12:00am

MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors. The study, announced...

Science and Environment